Interim Oncology Chief Medical Officer Alacrita provided interim chief medical officer support to an oncology company over the course of two years. The company was a developing a portfolio of first in class small molecules to treat a range of tumor types. Three of the products were in Phase I clinical trials, the first and most advanced was recruiting patients in a range of hematologic malignancies including acute myeloid leukemia, myeloid dysplastic syndrome and chronic lymphocytic leukemia. The second and third molecules were subject of Phase I/II trials in specific solid tumors. Challenge The company is well-capitalized with around 80 employees. The programs were discovered internally by the company’s cancer research efforts and were spearheading the company’s transition from a research

Join for free to read